SNDX

13.65

0.89% 0.12

Dopo l'orario di chiusura: 13.51 -0.14 -1.03%

Syndax Pharmaceuticals Inc (SNDX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$13.53

Aprire:

$13.58

Volume 24 ore:

2.63M

Relative Volume:

1.06

Capitalizzazione di mercato:

$1.22B

Reddito:

$217.42M

Utile/perdita netta:

$-243.25M

Rapporto P/E:

-4.8834

EPS:

-2.7952

Flusso di cassa netto:

$-278.35M

1 W Prestazione:

-19.23%

1M Prestazione:

-24.54%

6M Prestazione:

-43.90%

1 anno Prestazione:

-9.24%

Intervallo 1D:

$13.43

$14.05

Intervallo di 1 settimana:

$13.39

$17.42

Portata 52W:

$12.99

$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Nome

Syndax Pharmaceuticals Inc

Settore

Healthcare (1051)

Industria

Biotechnology (593)

Telefono

781-419-1400

Indirizzo

730 THIRD AVENUE, NEW YORK, MA

Dipendente

298

Cinguettio

@syndax

Prossima data di guadagno

2026-11-02

Ultimi documenti SEC

SNDX's Discussions on Twitter

Compare SNDX vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SNDX Syndax Pharmaceuticals Inc	13.65	1.22B	217.42M	-243.25M	-278.35M	-2.7952
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-16	Ripresa	H.C. Wainwright	Buy
2025-09-10	Ripresa	Stifel	Buy
2025-09-04	Ripresa	Guggenheim	Buy
2025-08-05	Reiterato	BTIG Research	Buy
2025-07-10	Iniziato	Goldman	Buy
2024-10-24	Iniziato	UBS	Buy
2024-06-28	Iniziato	Jefferies	Buy
2024-01-31	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2023-12-22	Iniziato	Mizuho	Buy
2023-10-25	Iniziato	BofA Securities	Buy
2023-10-11	Iniziato	Goldman	Buy
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-07-11	Iniziato	Guggenheim	Buy
2023-04-17	Ripresa	BTIG Research	Buy
2023-01-31	Iniziato	Stifel	Buy
2023-01-03	Iniziato	JP Morgan	Overweight
2022-07-28	Ripresa	B. Riley Securities	Buy
2022-04-11	Iniziato	H.C. Wainwright	Buy
2022-02-15	Iniziato	Goldman	Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-05-25	Iniziato	Citigroup	Buy
2021-02-18	Iniziato	B. Riley Securities	Buy
2020-12-03	Iniziato	Stifel	Buy
2020-05-22	Aggiornamento	Citigroup	Neutral → Buy
2020-05-22	Downgrade	H.C. Wainwright	Buy → Neutral
2020-05-18	Downgrade	Citigroup	Buy → Neutral
2020-05-11	Reiterato	H.C. Wainwright	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Reiterato	H.C. Wainwright	Buy
2019-03-08	Reiterato	H.C. Wainwright	Buy
2019-01-04	Iniziato	Robert W. Baird	Outperform
2018-01-05	Iniziato	B. Riley FBR, Inc.	Buy
2017-03-16	Iniziato	FBR & Co.	Outperform
2017-03-02	Iniziato	Instinet	Buy
2016-10-07	Iniziato	Guggenheim	Buy
2016-03-28	Iniziato	Citigroup	Buy
2016-03-28	Iniziato	JMP Securities	Mkt Outperform
2016-03-28	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie

Oct 14, 2026

Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? - Simply Wall Street

Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research

Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - TradingView

Oct 14, 2026

Oct 13, 2026

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PR Newswire

Oct 13, 2026

Syndax Pharmaceuticals Suffers Pipeline BlowSyndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga

Oct 13, 2026

Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $37.27, Implies 125% Upside - TradingView

Oct 13, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownHere's What Happened - MarketBeat

Oct 13, 2026

Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. - Barron's

Oct 13, 2026

Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says - Yahoo Finance

Oct 13, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed as Buy by HC Wainwright - MarketBeat

Oct 13, 2026

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Oct 13, 2026

Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? - Yahoo Finance

Oct 13, 2026

Oct 12, 2026

Syndax Pharmaceuticals ends IPF development after Phase 2 axatilimab miss - Mugglehead Investment Magazine

Oct 12, 2026

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Yahoo Finance

Oct 12, 2026

Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria - GuruFocus

Oct 12, 2026

Syndax says mid-stage trial of lung disease treatment fails main goal, ends development - Yahoo Finance

Oct 12, 2026

Syndax Pharmaceuticals stock tumbles on failed IPF trial - Yahoo Finance

Oct 12, 2026

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewswire

Oct 12, 2026

Oct 10, 2026

Possible Bearish Signals With Syndax Pharmaceuticals Insiders Disposing Stock - Moomoo

Oct 10, 2026

Oct 09, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat

Oct 09, 2026

Oct 02, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving AverageHere's What Happened - MarketBeat

Oct 02, 2026

Sep 30, 2026

Cash flow from investing activities of Syndax Pharmaceuticals Inc – HAN:1T3 - TradingView

Sep 30, 2026

Sep 28, 2026